PURPOSE: To evaluate the role of CD4(+) T cells in the development of murine herpes stromal keratitis (HSK). METHODS: The corneas of wild-type (WT) BALB/c mice and three types of CD4-deficient BALB/c mice (CD4(-/-), CD4-depleted, CD4 and CD8 double-depleted) were infected with different doses of HSV-1 RE, and HSK incidence and severity were monitored. Corneal infiltrates were quantitatively and functionally assayed by flow cytometric analysis of individually digested diseased corneas and documented histologically. RESULTS: At a relatively high infectious dose (1 x 10(5) pfu/cornea): (1) CD4-deficient and WT BALB/c mice had severe HSK with a similar incidence (80%-100%), whereas HSK did not develop in mice deficient in both CD4(+) and CD8(+) T cells; (2) neutrophils were the predominate leukocyte in the corneas of CD4-deficient and WT mice; (3) the corneas of WT mice had activated, HSV-1-specific CD4(+) T cells, but few if any CD8(+) T cells; (4) the corneas of CD4-deficient mice had activated, HSV-1-specific CD8(+) T cells; and (5) HSK in CD4-deficient mice was transient, showing loss of CD8(+) T cells at 2 to 3 weeks after infection (pi) followed by a loss of neutrophils. At a relatively low infectious dose of HSV-1 (10(3) pfu/cornea) severe HSK developed in 80% to 90% of WT mice, but in only 30% to 40% of CD4-deficient mice. CONCLUSIONS: CD4(+) T cells preferentially mediate HSK, but, in their absence, a high infectious dose of HSV-1 can induce histologically similar but transient HSK that is mediated by CD8(+) T cells.
PURPOSE: To evaluate the role of CD4(+) T cells in the development of murine herpes stromal keratitis (HSK). METHODS: The corneas of wild-type (WT) BALB/c mice and three types of CD4-deficient BALB/c mice (CD4(-/-), CD4-depleted, CD4 and CD8 double-depleted) were infected with different doses of HSV-1 RE, and HSK incidence and severity were monitored. Corneal infiltrates were quantitatively and functionally assayed by flow cytometric analysis of individually digested diseased corneas and documented histologically. RESULTS: At a relatively high infectious dose (1 x 10(5) pfu/cornea): (1) CD4-deficient and WT BALB/c mice had severe HSK with a similar incidence (80%-100%), whereas HSK did not develop in mice deficient in both CD4(+) and CD8(+) T cells; (2) neutrophils were the predominate leukocyte in the corneas of CD4-deficient and WT mice; (3) the corneas of WT mice had activated, HSV-1-specific CD4(+) T cells, but few if any CD8(+) T cells; (4) the corneas of CD4-deficient mice had activated, HSV-1-specific CD8(+) T cells; and (5) HSK in CD4-deficient mice was transient, showing loss of CD8(+) T cells at 2 to 3 weeks after infection (pi) followed by a loss of neutrophils. At a relatively low infectious dose of HSV-1 (10(3) pfu/cornea) severe HSK developed in 80% to 90% of WT mice, but in only 30% to 40% of CD4-deficient mice. CONCLUSIONS:CD4(+) T cells preferentially mediate HSK, but, in their absence, a high infectious dose of HSV-1 can induce histologically similar but transient HSK that is mediated by CD8(+) T cells.
Authors: Katharina M Huster; Vily Panoutsakopoulou; Kenya Prince; Marie E Sanchirico; Harvey Cantor Journal: Eur J Immunol Date: 2002-05 Impact factor: 5.532
Authors: V Panoutsakopoulou; M E Sanchirico; K M Huster; M Jansson; F Granucci; D J Shim; K W Wucherpfennig; H Cantor Journal: Immunity Date: 2001-07 Impact factor: 31.745
Authors: Alexander M Rowe; Hongming Yun; Benjamin R Treat; Paul R Kinchington; Robert L Hendricks Journal: J Immunol Date: 2017-01-06 Impact factor: 5.422
Authors: Lbachir BenMohamed; Nelson Osorio; Arif A Khan; Ruchi Srivastava; Lei Huang; John J Krochmal; Jairo M Garcia; Jennifer L Simpson; Steven L Wechsler Journal: Curr Eye Res Date: 2015-09-23 Impact factor: 2.424
Authors: Arif A Khan; Ruchi Srivastava; Aziz A Chentoufi; Elizabeth Kritzer; Sravya Chilukuri; Sumit Garg; David C Yu; Hawa Vahed; Lei Huang; Sabrina A Syed; Julie N Furness; Tien T Tran; Nesburn B Anthony; Christine E McLaren; John Sidney; Alessandro Sette; Randolph J Noelle; Lbachir BenMohamed Journal: J Immunol Date: 2017-05-24 Impact factor: 5.422
Authors: Gregory M Frank; Sherrie J Divito; Dawn M Maker; Min Xu; Robert L Hendricks Journal: Invest Ophthalmol Vis Sci Date: 2010-03-05 Impact factor: 4.799
Authors: Hongmin Yun; Michael B Yee; Kira L Lathrop; Paul R Kinchington; Robert L Hendricks; Anthony J St Leger Journal: Immunity Date: 2020-11-17 Impact factor: 31.745